Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Nature Medicine

Volumn 22, Issue 6, 2016, Pages 614-623

  Ishizuka, Andrew S ^a,k   Lyke, Kirsten E ^b,k   DeZure, Adam ^a   Berry, Andrea A ^b   Richie, Thomas L ^c   Mendoza, Floreliz H ^a   Enama, Mary E ^a   Gordon, Ingelise J ^a   Chang, Lee Jah ^a,j   Sarwar, Uzma N ^a,j   Zephir, Kathryn L ^a   Holman, Lasonji A ^a   James, Eric R ^c   Billingsley, Peter F ^c   Gunasekera, Anusha ^c   Chakravarty, Sumana ^c   Manoj, Anita ^c   Li, Minglin ^c,d   Ruben, Adam J ^c   Li, Tao ^c   Eappen, Abraham G ^c   Stafford, Richard E ^c,d   Natasha, K C ^c,d   Murshedkar, Tooba ^c   DeCederfelt, Hope ^e   Plummer, Sarah H ^a   Hendel, Cynthia S ^a   Novik, Laura ^a   Costner, Pamela J M ^a   Saunders, Jamie G ^a   Laurens, Matthew B ^b   Plowe, Christopher V ^b   Flynn, Barbara ^a   Whalen, William R ^a   Todd, J P ^a   Noor, Jay ^a   Rao, Srinivas ^a,j   Sierra Davidson, Kailan ^a   Lynn, Geoffrey M ^a   Epstein, Judith E ^f   Kemp, Margaret A ^e   Fahle, Gary A ^e   Mikolajczak, Sebastian A ^g   Fishbaugher, Matthew ^g   Sack, Brandon K ^g   Kappe, Stefan H I ^g   Davidson, Silas A ^h   Garver, Lindsey S ^h   Björkström, Niklas K ⁱ   Nason, Martha C ^a   Graham, Barney S ^a   Roederer, Mario ^a   Kim Lee Sim, B ^c,d   Hoffman, Stephen L ^c,l   Ledgerwood, Julie E ^a,l   Seder, Robert A ^a,l   more..

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c SANARIA INC   (United States)

^d Protein Potential LLC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NAVAL MEDICAL RESEARCH CENTER   (United States)

^g SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^h WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

ⁱ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^j SANOFI   (France)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l SANOFI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GAMMA INTERFERON; MALARIA VACCINE; PFSPZ VACCINE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; LIVER; MALARIA; MALARIA CONTROL; MALE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PARASITEMIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION; ADOLESCENT; ADULT; ANIMAL; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALARIA, FALCIPARUM; MIDDLE AGED; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RHESUS MONKEY; VACCINE IMMUNOGENICITY; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, PROTOZOAN; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGENICITY, VACCINE; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LIVER; MACACA MULATTA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITEMIA; PLASMODIUM FALCIPARUM; SPOROZOITES; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84966605853     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4110     Document Type: Article

References (49)

1. World Health Organization. World malaria report 2015. (World Health Organization, 2015).
2. Hoffman, S.L. et al. The march toward malaria vaccines. Vaccine 33, D13-D23 (2015).
3. Kester, K.E. et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS, S/AS01B and RTS, S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200, 337-346 (2009).
4. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomized, controlled trial. Lancet 386, 31-45 (2015).
5. Plowe, C.V., Alonso, P. & Hoffman, S.L. The potential role of vaccines in the elimination of falciparum malaria and the eventual eradication of malaria. J. Infect. Dis. 200, 1646-1649 (2009).
6. malERA Consultative Group on Vaccines. A research agenda for malaria eradication: vaccines. PLoS Med. 8, e1000398 (2011).
7. Roestenberg, M. et al. Long-Term protection against malaria after experimental sporozoite inoculation: An open-label follow-up study. Lancet 377, 1770-1776 (2011).
8. Hoffman, S.L. et al. Protection of humans against malaria by immunization with radiation-Attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
9. Hoffman, S.L. et al. Development of a metabolically active, nonreplicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6, 97-106 (2010).
10. Epstein, J.E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475-480 (2011).
11. Seder, R.A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359-1365 (2013).
12. Nganou-Makamdop, K. et al. Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Parasite Immunol. 34, 562-569 (2012).
13. Kramer, L.D. & Vanderberg, J.P. Intramuscular immunization of mice with irradiated Plasmodium berghei sporozoites. Enhancement of protection with albumin. Am. J. Trop. Med. Hyg. 24, 913-916 (1975).
14. Potocnjak, P., Yoshida, N., Nussenzweig, R.S. & Nussenzweig, V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151, 1504-1513 (1980).
15. Charoenvit, Y. et al. Monoclonal, but not polyclonal, antibodies protect against Plasmodium yoelii sporozoites. J. Immunol. 146, 1020-1025 (1991).
16. Charoenvit, Y. et al. Inability of malaria vaccine to induce antibodies to a protective epitope within its sequence. Science 251, 668-671 (1991).
17. Schofield, L. et al. Gamma interferon, CD8+ T cells, and antibodies required for immunity to malaria sporozoites. Nature 330, 664-666 (1987).
18. Weiss, W.R., Sedegah, M., Beaudoin, R.L., Miller, L.H. & Good, M.F. CD8+ T cells (cytotoxic and suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. USA 85, 573-576 (1988).
19. Doolan, D.L. & Hoffman, S.L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462 (2000).
20. Weiss, W.R. & Jiang, C.G. Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS One 7, e31247 (2012).
21. Tsuji, M. et al. γδ T cells contribute to immunity against the liver stages of malaria in αβ T cell-deficient mice. Proc. Natl. Acad. Sci. USA 91, 345-349 (1994).
22. Tse, S.W., Radtke, A.J., Espinosa, D.A., Cockburn, I.A. & Zavala, F. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8+ T cells specific for infectious pathogens. J. Infect. Dis. 210, 1508-1516 (2014).
23. Plotkin, S.A. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. J. 20, 63-75 (2001).
24. Sack, B.K. et al. Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect. Immun. 82, 808-817 (2014).
25. McElroy, A.K. et al. Human Ebola virus infection results in substantial immune activation. Proc. Natl. Acad. Sci. USA 112, 4719-4724 (2015).
26. Tse, S.W., Cockburn, I.A., Zhang, H., Scott, A.L. & Zavala, F. Unique transcriptional profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites. Genes Immun. 14, 302-309 (2013).
27. Chen, Z.W. Multifunctional immune responses of HMBPP-specific Vγ2Vδ2 T cells in M.Tuberculosis and other infections. Cell. Mol. Immunol. 10, 58-64 (2013).
28. Morita, C.T., Jin, C., Sarikonda, G. & Wang, H. Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens. Immunol. Rev. 215, 59-76 (2007).
29. Brandes, M., Willimann, K. & Moser, B. Professional antigen-presentation function by human γδ T cells. Science 309, 264-268 (2005).
30. Brandes, M. et al. Cross-presenting human γδ T cells induce robust CD8+ αβ T cell responses. Proc. Natl. Acad. Sci. USA 106, 2307-2312 (2009).
31. Inoue, S. et al. Enhancement of dendritic cell activation via CD40 ligand-expressing γδ T cells is responsible for protective immunity to Plasmodium parasites. Proc. Natl. Acad. Sci. USA 109, 12129-12134 (2012).
32. D'Ombrain, M.C. et al. Association of early interferon-γ production with immunity to clinical malaria: A longitudinal study among Papua New Guinean children. Clin. Infect. Dis. 47, 1380-1387 (2008).
33. Teirlinck, A.C. et al. Longevity and composition of cellular immune responses following experimental Plasmodium falciparum malaria infection in humans. PLoS Pathog. 7, e1002389 (2011).
34. Hoffman, S.L. et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244, 1078-1081 (1989).
35. Weiss, W.R. et al. A T cell clone directed at the circumsporozoite protein that protects mice against both Plasmodium yoelii and Plasmodium berghei. J. Immunol. 149, 2103-2109 (1992).
36. Amino, R. et al. Quantitative imaging of Plasmodium transmission from mosquito to mammal. Nat. Med. 12, 220-224 (2006).
37. Cockburn, I.A. et al. In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages. Proc. Natl. Acad. Sci. USA 110, 9090-9095 (2013).
38. Schmidt, N.W., Butler, N.S., Badovinac, V.P. & Harty, J.T. Extreme CD8 T cell requirements for antimalarial liver-stage immunity following immunization with radiation-Attenuated sporozoites. PLoS Pathog. 6, e1000998 (2010).
39. Gaziano, T.A., Young, C.R., Fitzmaurice, G., Atwood, S. & Gaziano, J.M. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: The NHANES I follow-up study cohort. Lancet 371, 923-931 (2008).
40. Food and Drug Administration. Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials (Food and Drug Administration, 2007).
41. Lyke, K.E. et al. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5, e13490 (2010).
42. Chulay, J.D. et al. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum. Am. J. Trop. Med. Hyg. 35, 66-68 (1986).
43. Rickman, L.S. et al. Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am. J. Trop. Med. Hyg. 43, 441-445 (1990).
44. Lamoreaux, L., Roederer, M. & Koup, R. Intracellular cytokine optimization and standard operating procedure. Nat. Protoc. 1, 1507-1516 (2006).
45. Lecluyse, E.L. & Alexandre, E. Isolation and culture of primary hepatocytes from resected human liver tissue. Methods Mol. Biol. 640, 57-82 (2010).
46. National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn. (The National Academies Press, 2011).
47. Vaughan, A.M. et al. A transgenic Plasmodium falciparum NF54 strain that expresses GFP-luciferase throughout the parasite life cycle. Mol. Biochem. Parasitol. 186, 143-147 (2012).
48. Miller, J.L. et al. Quantitative bioluminescent imaging of pre-erythrocytic malaria parasite infection using luciferase-expressing Plasmodium yoelii. PLoS One 8, e60820 (2013).
49. Roederer, M., Nozzi, J.L. & Nason, M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167-174 (2011).